iRadimed Corporation $IRMD Stock Holdings Lowered by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC lowered its position in shares of iRadimed Corporation (NASDAQ:IRMD) by 15.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 36,993 shares of the medical equipment provider’s stock after selling 6,600 shares during the period. Rice Hall James & Associates LLC owned 0.29% of iRadimed worth $3,599,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Farther Finance Advisors LLC grew its position in shares of iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 397 shares during the last quarter. Quarry LP bought a new position in shares of iRadimed during the third quarter worth about $40,000. CWM LLC grew its position in shares of iRadimed by 19.5% during the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after acquiring an additional 107 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 495 shares during the last quarter. Finally, USA Financial Formulas bought a new position in shares of iRadimed during the fourth quarter worth about $82,000. Institutional investors own 92.34% of the company’s stock.

Insider Transactions at iRadimed

In related news, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $100.38, for a total value of $501,900.00. Following the completion of the transaction, the chief executive officer owned 2,235,000 shares in the company, valued at $224,349,300. This represents a 0.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 55,000 shares of company stock valued at $5,031,903. Corporate insiders own 34.60% of the company’s stock.

iRadimed Stock Up 1.2%

Shares of IRMD opened at $91.84 on Wednesday. The firm has a 50-day moving average price of $90.69 and a 200 day moving average price of $95.90. The firm has a market capitalization of $1.17 billion, a PE ratio of 50.19 and a beta of 0.91. iRadimed Corporation has a 52-week low of $55.11 and a 52-week high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. The firm had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, equities analysts expect that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Friday, May 15th. iRadimed’s dividend payout ratio is currently 43.72%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Weiss Ratings lowered shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.